SMARCA4 and non-small cell lung carcinoma: Previous studies have indicated that SMARCA4 deficiency is associated with poor prognosis and reduced overall survival in NSCLC patients, as well as a higher likelihood of early postoperative recurrence and lower response rates to conventional treatments (4, 12).